HomeInfliximabInfliximab + Tocilizumab

Does Infliximab Interact with Tocilizumab?

Infliximab and Tocilizumab have a major drug interaction according to U.S. FDA drug labeling data. Concomitant use with infliximab should be avoided due to possibility of increased immunosuppression and increased risk of infection. The mechanism involves increased immunosuppression. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Infliximab Class
Tumor Necrosis Factor Blocker
Tocilizumab Class
Interleukin-6 Receptor Antagonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Infliximab and Tocilizumab occurs because increased immunosuppression. Clinically, this means concomitant use with infliximab should be avoided due to possibility of increased immunosuppression and increased risk of infection. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Infliximab and your doctor is considering prescribing Tocilizumab (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Infliximab(Inflectra)+💊 Tocilizumab(Tyenne)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Tumor Necrosis Factor Blocker
Drug B class
Interleukin-6 Receptor Antagonist
Source
NLP:infliximab

What this means in plain English

Concomitant use with infliximab should be avoided due to possibility of increased immunosuppression and increased risk of infection.

About Infliximab and Tocilizumab

Infliximab is a Tumor Necrosis Factor Blocker, while Tocilizumab is an Interleukin-6 Receptor Antagonist. You may recognize them by the brand names Inflectra and Tyenne. Both medications are given by intravenous (IV) infusion. Both Infliximab and Tocilizumab carry an FDA boxed warning — the agency's most serious safety designation.

What the FDA label says

"Increased immunosuppression"

📖 Source: NLP:infliximab

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Infliximab and Tocilizumab against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.